HEDULIN Drug Patent Profile
✉ Email this page to a colleague
When do Hedulin patents expire, and what generic alternatives are available?
Hedulin is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in HEDULIN is phenindione. There is one drug master file entry for this compound. Additional details are available on the phenindione profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for HEDULIN?
- What are the global sales for HEDULIN?
- What is Average Wholesale Price for HEDULIN?
Summary for HEDULIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 81 |
| Patent Applications: | 3,622 |
| DailyMed Link: | HEDULIN at DailyMed |
US Patents and Regulatory Information for HEDULIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | HEDULIN | phenindione | TABLET;ORAL | 008767-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
